Paraneoplastic antibodies coexist and predict cancer, not neurological syndrome

SJ Pittock, TJ Kryzer, VA Lennon - Annals of Neurology: Official …, 2004 - Wiley Online Library
SJ Pittock, TJ Kryzer, VA Lennon
Annals of Neurology: Official Journal of the American Neurological …, 2004Wiley Online Library
We investigated coexisting autoantibodies in sera of 553 patients with a neurological
presentation and one or more paraneoplastic neuronal nuclear or cytoplasmic
autoantibodies: antineuronal nuclear autoantibody type 1 (ANNA‐1), ANNA‐2, ANNA‐3;
Purkinje cell cytoplasmic autoantibody type 1 (PCA‐1), PCA‐2; and CRMP‐5–
immunoglobulin G or amphiphysin–immunoglobulin G. Except for PCA‐1, which occurred
alone, 31% of sera had more than one of these autoantibodies. In addition, 25% of sera had …
Abstract
We investigated coexisting autoantibodies in sera of 553 patients with a neurological presentation and one or more paraneoplastic neuronal nuclear or cytoplasmic autoantibodies: antineuronal nuclear autoantibody type 1 (ANNA‐1), ANNA‐2, ANNA‐3; Purkinje cell cytoplasmic autoantibody type 1 (PCA‐1), PCA‐2; and CRMP‐5–immunoglobulin G or amphiphysin–immunoglobulin G. Except for PCA‐1, which occurred alone, 31% of sera had more than one of these autoantibodies. In addition, 25% of sera had neuronal calcium channel (P/Q‐type or N‐type), potassium channel, ganglionic acetylcholine receptor, muscle acetylcholine receptor, or striational antibodies. The autoantibody profiles observed in patients with paraneoplastic disorders imply the targeting of multiple onconeural antigens and predict the patient's neoplasm, but not a specific neurological syndrome. Ann Neurol 2004
Wiley Online Library